<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Tacrolimus: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i730.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i730.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i730.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i728.htm" title="Previous: Terbutaline">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i945.htm" title="Next: Tadalafil">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i730">Tacrolimus</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Tacrolimus</b>
          has the following interaction information:
        </p><div>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i392.htm">Aciclovir</a></td><td>possible increased risk of nephrotoxicity when  tacrolimus given with aciclovir </td><td>Interactions do not apply to topical aciclovir preparations</td></tr><tr><td><a href="41001i128.htm">Aminoglycosides</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  tacrolimus given with aminoglycosides </b></td><td></td></tr><tr><td><a href="41001i290.htm" name="_290">Amphotericin</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  tacrolimus given with amphotericin </b></td><td>Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</td></tr><tr><td><a href="41001i107.htm" name="_107">Angiotensin-II Receptor Antagonists</a></td><td>increased risk of hyperkalaemia when  tacrolimus given with angiotensin-II receptor antagonists </td><td></td></tr><tr><td><a href="41001i293.htm">Antifungals, Imidazole</a></td><td class="cBV"><b>plasma concentration of  tacrolimus possibly increased by imidazoles </b></td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>plasma concentration of  tacrolimus possibly increased by atazanavir </b></td><td></td></tr><tr><td><a href="41001i947.htm">Caspofungin</a></td><td class="cBV"><b>plasma concentration of  tacrolimus reduced by caspofungin </b></td><td></td></tr><tr><td><a href="41001i158.htm">Chloramphenicol</a></td><td class="cBV"><b>plasma concentration of  tacrolimus possibly increased by chloramphenicol </b></td><td></td></tr><tr><td><a href="41001i499.htm" name="_499">Ciclosporin</a></td><td class="cBV"><b> tacrolimus increases plasma concentration of ciclosporin (increased risk of nephrotoxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>plasma concentration of  tacrolimus increased by clarithromycin </b></td><td></td></tr><tr><td><a href="41001i1120.htm" name="_1120">Dabigatran Etexilate</a></td><td class="cBV"><b> tacrolimus possibly increases plasma concentration of dabigatran etexilate—manufacturer of dabigatran etexilate advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i579.htm">Danazol</a></td><td>plasma concentration of  tacrolimus possibly increased by danazol </td><td></td></tr><tr><td><a href="41001i468.htm">Diltiazem</a></td><td class="cBV"><b>plasma concentration of  tacrolimus increased by diltiazem </b></td><td></td></tr><tr><td><a href="41001i544.htm" name="_544">Diuretics, Potassium-sparing and Aldosterone Antagonists</a></td><td class="cBV"><b>increased risk of hyperkalaemia when  tacrolimus given with potassium-sparing diuretics and aldosterone antagonists </b></td><td></td></tr><tr><td><a href="41001i1176.htm" name="_1176">Dronedarone</a></td><td>caution with  tacrolimus advised by manufacturer of dronedarone </td><td></td></tr><tr><td><a href="41001i1152.htm" name="_1152">Droperidol</a></td><td class="cBV"><b>avoidance of  tacrolimus advised by manufacturer of droperidol (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td class="cBV"><b>plasma concentration of  tacrolimus possibly affected by efavirenz </b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>plasma concentration of  tacrolimus increased by erythromycin </b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i638.htm">Ethinylestradiol</a></td><td>plasma concentration of  tacrolimus possibly increased by ethinylestradiol </td><td></td></tr><tr><td><a href="41001i471.htm">Felodipine</a></td><td>plasma concentration of  tacrolimus possibly increased by felodipine </td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td class="cBV"><b>plasma concentration of  tacrolimus increased by fluconazole (consider reducing dose of tacrolimus)</b></td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b>plasma concentration of  tacrolimus increased by fosamprenavir </b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i395.htm">Ganciclovir</a></td><td>possible increased risk of nephrotoxicity when  tacrolimus given with ganciclovir </td><td>Increased risk of myelosuppression with other myelosuppressive drugs—consult product literature</td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td class="cBV"><b>plasma concentration of  tacrolimus increased by grapefruit juice </b></td><td></td></tr><tr><td><a href="41001i783.htm" name="_783">Ibuprofen</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  tacrolimus given with ibuprofen </b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>plasma concentration of  tacrolimus increased by itraconazole (consider reducing dose of tacrolimus)</b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>plasma concentration of  tacrolimus increased by ketoconazole (consider reducing dose of tacrolimus)</b></td><td></td></tr><tr><td><a href="41001i1173.htm" name="_1173">Mifamurtide</a></td><td>avoidance of  tacrolimus advised by manufacturer of mifamurtide </td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>plasma concentration of  tacrolimus possibly increased by nelfinavir </b></td><td></td></tr><tr><td><a href="41001i474.htm">Nicardipine</a></td><td>plasma concentration of  tacrolimus possibly increased by nicardipine </td><td></td></tr><tr><td><a href="41001i475.htm">Nifedipine</a></td><td class="cBV"><b>plasma concentration of  tacrolimus increased by nifedipine </b></td><td></td></tr><tr><td><a href="41001i60.htm" name="_60">NSAIDs</a></td><td>possible increased risk of nephrotoxicity when  tacrolimus given with NSAIDs </td><td><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td>plasma concentration of  tacrolimus possibly increased by omeprazole </td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>plasma concentration of  tacrolimus reduced by phenobarbital </b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  tacrolimus reduced by phenytoin , also plasma concentration of phenytoin possibly increased</td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b>plasma concentration of  tacrolimus increased by posaconazole (consider reducing dose of tacrolimus)</b></td><td></td></tr><tr><td><a href="41001i662.htm" name="_662">Potassium Salts</a></td><td class="cBV"><b>increased risk of hyperkalaemia when  tacrolimus given with potassium salts </b></td><td>Includes salt substitutes</td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td>plasma concentration of  tacrolimus possibly reduced by rifabutin </td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  tacrolimus reduced by rifampicin </b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  tacrolimus possibly increased by ritonavir </b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>plasma concentration of  tacrolimus increased by saquinavir (consider reducing dose of tacrolimus)</b></td><td></td></tr><tr><td><a href="41001i1065.htm">Sevelamer</a></td><td>plasma concentration of  tacrolimus possibly reduced by sevelamer </td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  tacrolimus reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>plasma concentration of both drugs increased when  tacrolimus given with telaprevir (reduce dose of tacrolimus)</b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>plasma concentration of  tacrolimus possibly increased by telithromycin </b></td><td></td></tr><tr><td><a href="41001i218.htm">Vancomycin</a></td><td>possible increased risk of nephrotoxicity when  tacrolimus given with vancomycin </td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td>plasma concentration of  tacrolimus possibly increased by verapamil </td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>plasma concentration of  tacrolimus increased by voriconazole (consider reducing dose of tacrolimus)</b></td><td></td></tr></tbody></table></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i728.htm">Previous: Terbutaline</a> | <a class="top" href="41001i730.htm#">Top</a> | <a accesskey="]" href="41001i945.htm">Next: Tadalafil</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>